Selpercatinib shortage — AU supply status & alternatives

Selpercatinib

—

🇦🇺 AUST R 391331 · Eli Lilly Australia Pty Ltd

In shortage · Australia

Retsevmo

In declared shortage · 🇦🇺 Australia

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

🇦🇺 AUAEMPA$1975.00DPMQ A$2146.86details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names	Retsevmo

Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper

Controlled substance	No

Marketing-authorisation holders	Eli Lilly Australia Pty Ltd

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$1975.00

AEMP

Dispensed (DPMQ)

A$2146.86

incl. fees

Pack

Selpercatinib 40 mg capsule, 56

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

1 API manufacturer

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Very high concentration risk

Msn Laboratories Private LTD

Manufacturing countries: India · Source: FDA List of Drug Master Files

Verified timeline regulator events

🇮🇹 30 July 2026

Shortage resolved

🇦🇺 1 July 2026

high reported

🇮🇹 30 June 2026

Shortage resolved

🇮🇹 31 May 2026

Shortage resolved

🇮🇹 15 July 2022

Shortage resolved

🇮🇹 17 June 2022

Shortage resolved

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
RETEVMO selpercatinib	40 mg	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
RETEVMO selpercatinib	80 mg	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.